Physician profile
Stephen M Levy
NPI 1316947856
$2,051.96
in general payments reported to CMS, 2019-2025
18 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $125 · 2021: $389 · 2022: $499 · 2023: $194 · 2024: $311 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $602.44 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $331.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.04 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $212.09 | 2019-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $146.94 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $105.45 | 2019-2022 | |
| Atricure, INC. | $60.85 | 2022 | |
| Novo Nordisk INC | $59.67 | 2024 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $56.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.90 | 2020-2023 | Farxiga |
| Boston Scientific Corporation | $36.77 | 2019-2024 | Watchman Flx |
| Arbor Pharmaceuticals, INC. | $26.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.03 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.96 | 2024 | Lifevest |
| Medtronic, INC. | $19.99 | 2023 | Cobalt Dr Mri Surescan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.33 | 2019 | |
| Pfizer INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.